http://money.cnn.com/news/newsfeeds/...re/PH33434.htm.

Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated last week in the Phase I trial testing NSI-566 human neural stem cells in the treatment of chronic spinal cord injury (cSCI) at the UC San Diego School of Medicine. The patient has been discharged from the hospital. The NSI-566/cSCI Phase I trial will treat four patients who have thoracic spinal cord injuries (T2-T12) with stem cell transplants directly into the region of the injury, between one and two years post-injury. All of the patients have an American Spinal Injury Association (AIS) grade A level of impairment, which is complete paralysis with no motor or sensory function in the relevant segments at and below the injury. The trial is under the direction of principal investigator (PI) Joseph Ciacci, MD, UC San Diego School of Medicine and neurosurgeon at UC San Diego Health System. Much of the pre-clinical work with the NSI-566 cells in spinal cord injury was conducted at UC San Diego School of Medicine by Martin Marsala, MD, professor in the Department of Anesthesiology, who will be another study investigator.
Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer, explained the scientific rationale behind the Neuralstem therapy. "The therapeutic mechanism of action for the neural stem cell transplantation in chronic spinal cord injury is for the transplant to 'bridge the circuitry gap' in the cord which resulted from the injury. To return meaningful function to the patients, existing nerves from above the injury will need to traverse and connect to the intact area below the injury, which we believe can happen via our transplant. The new nerves generated from the transplant itself can connect to the host cord above and below the injury and contribute to the rebuilding of the damaged circuitry, as demonstrated in animal studies (Lu, Gorp). This structural repair by NSI-566 in chronic SCI patients will be in addition to the neuroprotective factor expression demonstrated in ALS patients who have undergone transplantation with the same cells."
This clinical trial at UC San Diego Health System is funded by Neuralstem, Inc. and was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.